Keywords: avi, biopharma, enters, clinic, resten-ng, begun, human

AVI BioPharma enters clinic with Resten-NG

Article | 20 December 1999

Print This

AVI BioPharma has begun human trials of Resten-NG, its gene therapyfor cardiovascular restenosis, and the first compound from its NeuGene ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in